Vilya pioneers computational drug design, creating entirely new de novo macrocycles inspired by biology and designed using AI. Their platform generates, predicts, and validates these molecules in silico, aiming to develop orally bioavailable therapies that combine the selectivity of biologics with the convenience of pills. Vilya serves the pharmaceutical and biotechnology industries by advancing a new class of medicines for previously untreatable diseases.